| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 08.09. | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.06. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | AEON Biopharma, Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
| 11.06. | AEON Biopharma, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 23.05. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 190 | GlobeNewswire (Europe) | IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 20.05. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | AEON Biopharma GAAP EPS of $2.28 | 1 | Seeking Alpha | ||
| 14.05. | AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | 179 | GlobeNewswire (Europe) | - Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen | |
| 25.04. | AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance | 715 | GlobeNewswire (Europe) | IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 21.04. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 140 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 21.04. | AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer | 740 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 24.03. | AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 445 | GlobeNewswire (Europe) | - Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen | |
| 24.02. | AEON Biopharma, Inc. Announces Reverse Stock Split | 252 | GlobeNewswire (Europe) | IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under... ► Artikel lesen | |
| 07.02. | AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards | 240 | GlobeNewswire (Europe) | IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under... ► Artikel lesen | |
| 13.11.24 | AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 233 | GlobeNewswire (Europe) | - Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA)... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALTERITY THERAPEUTICS | 0,005 | 0,00 % | XFRA PBN: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BIOCURE TECHNOLOGY | 0,032 | 0,00 % | Biocure Technology Inc (2): Biocure shareholders approve all matters at AGM | ||
| AVIDITY BIOSCIENCES | 69,91 | 0,00 % | Biotech-Boom: Novartis übernimmt Avidity Biosciences für 12 Milliarden US$ | Der Schweizer Pharmakonzern Novartis hat einen bedeutenden Schritt in der Erweiterung seines Portfolios gemacht. Mit der Übernahme des US-Biotechnologieunternehmens Avidity Biosciences stärkt Novartis... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,290 | +0,50 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| ARCUTIS BIOTHERAPEUTICS | 25,010 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| 89BIO | 14,835 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,520 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 199,36 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,320 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,970 | -2,52 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,910 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| JANUX THERAPEUTICS | 29,760 | 0,00 % | Janux Therapeutics gains amid renewed takevover speculation | ||
| ADMA BIOLOGICS | 15,600 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| IMMUNOVANT | 21,995 | 0,00 % | Immunovant Inc.: Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 | ||
| SUMMIT THERAPEUTICS | 19,250 | 0,00 % | Summit Therapeutics: A Risky Bet in the Biotech Arena? |